APA (7th ed.) Citation

Martin, D. E., Blum, R., Wilton, J., Doto, J., Galbraith, H., Burgess, G. L., . . . Ballow, C. (2007). Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 51(9), 3063-3066. https://doi.org/10.1128/AAC.01391-06

Chicago Style (17th ed.) Citation

Martin, David E., Robert Blum, John Wilton, Judy Doto, Hal Galbraith, Gina L. Burgess, Philip C. Smith, and Charles Ballow. "Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers." Antimicrobial Agents and Chemotherapy 51, no. 9 (2007): 3063-3066. https://doi.org/10.1128/AAC.01391-06.

MLA (9th ed.) Citation

Martin, David E., et al. "Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers." Antimicrobial Agents and Chemotherapy, vol. 51, no. 9, 2007, pp. 3063-3066, https://doi.org/10.1128/AAC.01391-06.